0001209191-21-037482.txt : 20210602 0001209191-21-037482.hdr.sgml : 20210602 20210602214722 ACCESSION NUMBER: 0001209191-21-037482 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210601 FILED AS OF DATE: 20210602 DATE AS OF CHANGE: 20210602 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Ali-Jackson Kamil CENTRAL INDEX KEY: 0001654337 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37581 FILM NUMBER: 21991096 MAIL ADDRESS: STREET 1: C/O ACLARIS THERAPEUTICS, INC. STREET 2: 101 LINDENWOOD DRIVE, SUITE 400 CITY: MALVERN STATE: PA ZIP: 19355 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Aclaris Therapeutics, Inc. CENTRAL INDEX KEY: 0001557746 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 460571712 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 640 LEE ROAD STREET 2: SUITE 200 CITY: WAYNE STATE: PA ZIP: 19087 BUSINESS PHONE: 484-324-7933 MAIL ADDRESS: STREET 1: 640 LEE ROAD STREET 2: SUITE 200 CITY: WAYNE STATE: PA ZIP: 19087 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-06-01 0 0001557746 Aclaris Therapeutics, Inc. ACRS 0001654337 Ali-Jackson Kamil C/O ACLARIS THERAPEUTICS, INC. 640 LEE ROAD, SUITE 200 WAYNE PA 19087 0 1 0 0 Chief Legal Officer Common Stock 2021-06-01 4 M 0 33189 A 176807 D Common Stock 2021-06-01 4 S 0 9746 22.7219 D 167061 D Common Stock 2021-06-01 4 S 0 5254 23.5728 D 161807 D Common Stock 2021-06-02 4 S 0 12483 21.5022 D 149324 D Common Stock 2021-06-02 4 S 0 2517 22.3175 D 146807 D Common Stock 2021-06-02 4 S 0 12732 21.5066 D 134075 D Common Stock 2021-06-02 4 S 0 2387 22.3112 D 131688 D Restricted Stock Units 2021-06-01 4 M 0 33189 0.00 D Common Stock 33189 0 D Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2021. The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $22.25 to $23.17, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $23.27 to $23.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $21.03 to $22.01, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $22.06 to $22.72, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for restricted stock units that vested on June 1, 2021 pursuant to preexisting sell-to-cover elections. The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $21.06 to $22.05, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $22.07 to $22.72, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The shares underlying these restricted stock units vested in two equal annual installments beginning on June 1, 2020. /s/ Mark Ballantyne, Attorney-in-Fact 2021-06-02